Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | Avg patent value: 1.94 M | |||
2 | Avg patent value: 290,000 | |||
3 | Avg patent value: 91,218 | |||
4 |  STARTUP | Avg patent value: 45,500 | ||
5 | Avg patent value: 38,200 |
Top 5 Key Players companies in PCSK9 Inhibitors
by Highest Patent Value in the United States in 2018
The PCSK9 Inhibitors top 5 is Discovery PatSnap’ annual ranking of the top 5 Highest Patent Value PCSK9 Inhibitors Key Players in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2018, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
Page generation time:
May 17 2025